Has Neslihan Gungor received payments from drug or device companies?

Yes. Drug and device makers reported $16,003 in general payments to Neslihan Gungor across 94 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neslihan Gungor did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neslihan Gungor come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neslihan Gungor

Pediatrics · Shreveport, LANPI 1275782120

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,992 of the $16,003 with a category attached, or 68.7%. Sanofi accounts for 77.4% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $14,218, more than ten times the $124 reported in 2019. Among pediatrics clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,003in general payments, 2019–2025

Across 94 payments — averaging $170.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$12K
Medtronic$1K
Ascendis Pharma Endocrinology Inc$403
Tolmar, Inc.$300
Novo Nordisk$294
Kyowa Kirin, Inc.$235
plus $1K from 19 others

What the payments were for

Consulting fees$10,99269%
Travel & lodging$1,92812%
Food & beverage$2,80318%
Education$2802%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	7	$12,385
Medtronic	11	$1,250
Ascendis Pharma Endocrinology Inc	8	$403
Tolmar, Inc.	8	$300
Novo Nordisk	10	$294
Kyowa Kirin, Inc.	7	$235
Shire North American Group Inc	1	$124
Arbor Pharmaceuticals, Inc.	1	$115
Dexcom, Inc.	4	$98
AbbVie	4	$83
AstraZeneca	3	$83
Soleno Therapeutics, Inc.	3	$71
Sanofi-aventis U.S. LLC	3	$70
Tandem Diabetes Care, Inc.	3	$64
Insulet Corporation	3	$61
Pfizer	3	$57
Biomarin Pharmaceutical Inc.	2	$48
Tolmar Pharmaceuticals, Inc.	2	$46
Neurocrine Biosciences, Inc.	2	$45
Xeris Pharmaceuticals, Inc.	2	$41
IBSA Pharma Inc.	2	$36
BETA Bionics, Inc.	2	$34
Ultragenyx Pharmaceutical Inc.	1	$24
Sequel Med Tech, LLC	1	$20
Azurity Pharmaceuticals, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,003 in reported general payments places this provider in the 95th percentile of 913 pediatrics providers in Louisiana.

See all pediatrics providers in Louisiana →

Other pediatrics in Shreveport

Mamatha MandavaShreveport$8K
Kendra LandryShreveport$5K
Lori PhillipsShreveport$3K
Margaret CrittellShreveport$3K
Donald MackShreveport$3K
Mackey QuinlanShreveport$3K
Stuart ClarkShreveport$2K
Corey HebertGretna$1.3M
Katie QueenBogalusa$61K
Elizabeth WhiteCovington$19K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →